Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
novartis
8
×
zolgensma
8
×
biotech
clinical trials
gene therapy
national blog main
national top stories
boston blog main
national
new york top stories
boston top stories
fda
new york blog main
san francisco top stories
biogen
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
seattle blog main
seattle top stories
spinal muscular atrophy
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
avexis
bristol-myers squibb
deals
glaxosmithkline
johnson & johnson
abbvie
What
roundup
bio
biotech
drug
news
therapy
fda
gene
healthcare
nash
new
past
public
topped
access
according
advanced
age
akcea
america
approval
approved
atrophy
august
bigger
biggest
biogen
biogen’s
biopharmaceutical
busy
capacity
car
cases
cell
centers
cigarettes
come
companies
consolidation
continues
Language
unset
Current search:
zolgensma
×
novartis
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Drug Pricing: Innovation, Investment, and the Public Good
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
With $100M MeiraGTx Deal, J&J Signals Bigger Move Into Gene Therapy